IART übertreffen die 23 der letzten 40Schätzungen.
57%
Nächster Bericht
Datum des nächsten Berichts
23. Feb. 2026
Estimate forQ4 25(Revenue/ EPS)
$438.21M
/
$0.81
Implizierte Änderung vonQ3 25(Revenue/ EPS)
+8.99%
/
+50.00%
Implizierte Änderung vonQ4 24(Revenue/ EPS)
-1.00%
/
-16.49%
Integra LifeSciences Holdings earnings per share and revenue
On 30. Okt. 2025, IART reported earnings of 0.54 USD per share (EPS) for Q3 25, beating the estimate of 0.44 USD, resulting in a 21.70% surprise. Revenue reached 402.06 million, compared to an expected 422.54 million, with a -4.85% difference. The market reacted with a -23.46% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 12 analysts forecast an EPS of 0.81 USD, with revenue projected to reach 438.21 million USD, implying an increase of 50.00% EPS, and increase of 8.99% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AngioDynamics, Inc.
Report Date
06. Jan. 2026 For Q2 26
Estimate
-$0.10
Aktuell
$0.00
Überraschung
+100.00%
FAQ
What were Integra LifeSciences Holdings's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Integra LifeSciences Holdings reported EPS of $0.54, beating estimates by 21.7%, and revenue of $402.06M, -4.85% below expectations.
How did the market react to Integra LifeSciences Holdings's Q3 2025 earnings?
The stock price moved down -23.46%, changed from $15.43 before the earnings release to $11.81 the day after.
When is Integra LifeSciences Holdings expected to report next?
The next earning report is scheduled for 23. Feb. 2026.
What are the forecasts for Integra LifeSciences Holdings's next earnings report?
Based on 12
analysts, Integra LifeSciences Holdings is expected to report EPS of $0.81 and revenue of $438.21M for Q4 2025.